<DOC>
	<DOCNO>NCT01882933</DOCNO>
	<brief_summary>A prospective , open , multicentric , randomise , phase III trial two arm : - Arm A : curative gastrectomy D1-D2 lymph node dissection + HIPEC oxaliplatin - Arm B : curative gastrectomy D1-D2 lymph node dissection Main objective : Compare overall 5-year survival rate patient surgically treat advanced gastric adenocarcinoma ( T3 , T4 and/or N+ and/or positive peritoneal cytology ) , treat either curative gastrectomy adjuvant HIPEC , curative gastrectomy alone .</brief_summary>
	<brief_title>D2 Resection HIPEC ( Hyperthermic Intraperitoneal Chemoperfusion ) Locally Advanced Gastric Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>18 &lt; age ≤ 75 year old White blood cell &gt; 3,500/mm3 , neutrophil ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 Good renal function , serum creatinine value &lt; 1.5 mg/dl creatinine clearance &gt; 60 ml/min Performance Status ≤1 , Karnofsky Index ≥ 70 % Serum bilirubin ≤ 2 mg/dl Having give write informed consent prior procedure relate study . Covered Health System applicable , and/or compliance recommendation national law force relate biomedical research Not administrative legal supervision Histologically evidence resectable T3 T4 gastric adenocarcinoma curative gastrectomy schedule , invasion serosa AND/OR lymph node metastasis ( determine data obtain endoscopic ultrasound chest , abdomen pelvis CT scan ) AND/OR positive peritoneal cytology ( sample preoperative laparoscopy ) . AND/OR Perforated gastric adenocarcinoma AND/OR Siewert III adenocarcinoma cardia gastrectomy exclusive abdominal laparotomy schedule Females childbearing age potential male subject partner childbearing potential use efficient contraceptive measure ( judge investigator ) .Subjects randomised arm HIPEC inform accept requirement also extend : 4 month treatment Oxaliplatin female subject , 6 month treatment Oxaliplatin male subject . Prior malignant tumor detectable sign recurrence Gastric stump adenocarcinoma Presence comorbidities , notably serious chronic disease organ failure General condition Any subject exclusion period previous study accord applicable regulation Pregnancy breastfeed Females childbearing age potential male subject partner childbearing potential use medically accept contraceptive measure , judge investigator Interfering substance Contraindication drug contain chemotherapy regimen Specific study Life threaten toxicity surgery Distant metastases ( liver , lung . ovary , etc ) Tumoral infiltration head body pancreas Patients present adenocarcinoma cardia Siewert I II Existence macroscopic peritoneal implant Patients clinically significant ascites ( &gt; 500 cc ) even cytology negative cancer cell , absence nonmalignant cause ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastric adenocarcinoma</keyword>
	<keyword>HIPEC</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Signet ring cell</keyword>
</DOC>